Tirzepatide Microdosing: What the Trial Data Says About Sub-Therapeutic Doses (And Why Most of It Is Off-Label)

Tirzepatide microdosing — using doses below the FDA-approved 2.5 mg starting dose — has become a popular strategy in patient communities, mostly for cost reasons (compounded vials are priced per mg) and side effect tolerance. The SURMOUNT-1 trial^[1] tested 5, 10, and 15 mg maintenance doses with a 2.5 mg starter; no formal trial has tested anything below 2.5 mg. This article walks through what the published dose-response curve actually shows, why any dose below the FDA-approved starting dose is off-label, and the conversation patients should have with their prescriber rather than self-microdosing in isolation.

What “microdosing” actually means in this context

In tirzepatide patient communities, “microdosing” typically refers to one of three things:

• Sub-2.5 mg doses (e.g., 1 mg, 1.25 mg, or 1.5 mg weekly) — below the FDA-approved 2.5 mg starting dose
• Staying on 2.5 mg indefinitely rather than escalating to the 5/10/15 mg maintenance doses — this is technically a label-allowed starter dose but not a maintenance dose per the prescribing information
• Splitting the weekly dose into two smaller injections (e.g., half-dose Mondays and half-dose Thursdays) — pharmacologically distinct from microdosing but often grouped under the same patient term

None of these is FDA-approved as a maintenance regimen for Zepbound or Mounjaro^[4][5]. The first and third are completely off-label; the second is on the label as a starter dose only.

The published SURMOUNT-1 dose-response data

SURMOUNT-1^[1] was the obesity registration trial for tirzepatide and tested three maintenance doses against placebo over 72 weeks in 2,539 adults with BMI ≥30 (or ≥27 with comorbidity). Mean weight loss at 72 weeks:

• Placebo — −3.1%
• Tirzepatide 5 mg — −16.0%
• Tirzepatide 10 mg — −19.5%
• Tirzepatide 15 mg — −20.9%

Notice the shape of the curve: the jump from placebo to 5 mg is large (16 percentage points), the jump from 5 mg to 10 mg is moderate (3.5 points), and the jump from 10 mg to 15 mg is small (1.4 points). The dose-response is steep at the low end and flattens at the high end. This is the scientific basis for the microdosing argument: if 5 mg produces 16% weight loss, what does 2.5 mg or 1.25 mg do?

What we know (and don't know) about doses below 5 mg

The 2.5 mg dose was used in SURMOUNT-1 as a 4-week starter dose only, not as a maintenance dose. There is no published 72-week efficacy result for tirzepatide 2.5 mg as a maintenance dose, and there is no published trial of any dose below 2.5 mg. Inferences from the SURMOUNT-1 dose-response curve and from the SURPASS diabetes trials^[2] suggest that:

• 2.5 mg as a starter produces a small amount of weight loss (~2-3% over 4 weeks in the trial run-in periods)
• 2.5 mg as a sustained dose would probably produce more weight loss than placebo but substantially less than 5 mg — extrapolating the dose-response curve
• 1-1.25 mg doses — completely uncharacterized in the published literature. We have no trial data on what they actually do

The pharmacokinetics^[3] are linear in the labeled dose range (2.5-15 mg), so a 1.25 mg dose would produce roughly half the steady-state plasma concentration of a 2.5 mg dose. Whether that produces meaningful weight loss is an empirical question that has not been answered.

Why patients microdose anyway

Three motivations dominate:

1. Cost. Compounded tirzepatide is priced per mg in many telehealth pharmacies. A 1.25 mg weekly regimen costs roughly half as much as a 2.5 mg regimen and a quarter as much as 5 mg. For patients paying out of pocket, the cost difference is large.
2. Side effect tolerance. Some patients who cannot tolerate the standard 2.5 mg starter dose due to nausea, vomiting, or fatigue find that a fractional dose is tolerable. For these patients, microdosing is the difference between staying on tirzepatide and stopping entirely.
3. Avoiding the “rebound” from full discontinuation. Patients who reach their goal weight on a higher dose but want to maintain on a lower dose to avoid the weight regain documented in the SURMOUNT-4 trial sometimes microdose as a maintenance strategy.

The risks and unknowns

• Efficacy is unknown at doses below 2.5 mg. Patients may believe they are getting a benefit that's not actually there (or that's smaller than expected).
• Compounded tirzepatide quality varies. A microdose from a high-quality PCAB-accredited compounder is a different thing from a microdose from a grey-market source. See our PCAB accreditation investigation for our vetting framework.
• Splitting weekly doses changes the pharmacokinetics. Tirzepatide's once-weekly dosing is designed for the ~5-day half-life. Splitting into two injections per week shifts the peak-to-trough ratio in ways that have not been formally studied.
• Off-label dosing puts the prescriber at higher risk. A prescriber writing for a non-labeled dose is taking on additional clinical and medicolegal exposure compared with a labeled dose. Some legitimate prescribers will not do it.
• Insurance and brand-name programs do not cover microdosing. Wegovy NovoCare, Zepbound LillyDirect, and most insurance formularies dispense in standard label doses only. Microdosing is essentially a compounded-pharmacy-only phenomenon.

The conversation to have with your prescriber

If you are considering microdosing tirzepatide — for cost, for tolerance, or for maintenance after goal weight — bring it up explicitly with your prescriber rather than doing it in isolation. Useful framing for that conversation:

• State the reason. Cost, tolerance, or maintenance? Each reason maps to different alternative strategies.
• Ask about staying on a lower labeled dose. For some patients, the right answer is to stay on Zepbound 5 mg long-term rather than escalating to 15 mg, or to de-escalate from 15 mg back to 10 mg or 5 mg as a maintenance strategy. These are still labeled doses but at the lower end.
• Ask about Foundayo (oral orforglipron) as an alternative. The new oral GLP-1 has a different titration schedule and more granular dose levels. For some cost-sensitive patients it's the better answer than microdosing tirzepatide.
• Document your weight and symptoms so you and your prescriber can tell whether the microdose is actually doing anything.
• Use a PCAB-accredited compounder if you go this route. The compounded supply chain is the weakest link.

What this article is NOT

This article does not endorse or recommend tirzepatide microdosing. There is no published efficacy or safety data at doses below 2.5 mg, and any dose below the FDA-approved starting dose is off-label^[6]. The article exists to answer the question patients are actually searching for, summarize the trial data that does exist, and redirect the decision back to a clinical conversation with a qualified prescriber.

Bottom line

• SURMOUNT-1 tested 5, 10, and 15 mg as maintenance doses and 2.5 mg as a 4-week starter. No formal trial has tested doses below 2.5 mg.
• The dose-response curve is steep at the low end and flattens at the high end — so a 5 mg dose is much closer to 15 mg in efficacy than the dose ratio would suggest.
• Doses below 2.5 mg are off-label and not characterized in the published literature. Inferring from linear PK, steady-state concentration scales with dose, but the weight-loss effect at fractional doses is unknown.
• Patient motivations for microdosing are real (cost, tolerance, maintenance), and there are sometimes better on-label alternatives (lower labeled dose, switching to Foundayo, switching to compounded semaglutide).
• If you choose to microdose, do it with your prescriber, a PCAB-accredited compounder, and documented monitoring — not in isolation.

Related research and tools

• Semaglutide microdosing evidence guide — same analysis for semaglutide
• GLP-1 dose plotter — visualize how each dose builds up in your bloodstream
• GLP-1 unit converter — mg ↔ insulin syringe units math for compounded vials
• Why am I not losing weight on a GLP-1? — the plateau response distribution
• Switching between GLP-1 medications
• Foundayo (orforglipron) approval deep-dive — the new oral option with different dose levels
• PCAB accreditation: how to vet a compounded pharmacy

Important disclaimer. This article is educational and does not constitute medical advice or a recommendation to use any particular dose of tirzepatide. Off-label dosing decisions should be made with a qualified prescriber who knows your medical history. Tirzepatide is FDA-approved as Zepbound and Mounjaro at the labeled doses only; any dose below 2.5 mg is unstudied, and any compounded supply should come from a PCAB-accredited pharmacy.